SCHEMBL14299995

SCHEMBL14299995

CC(C)(Sc1ccc(F)cc1F)C(=O)Nc1cc(C(F)(F)F)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.53
▸ KDR P35968 2/20 0.41
▸ CLK2 P49760 1/20 0.41
▸ IRAK1 P51617 1/20 0.41
▸ NEK4 P51957 1/20 0.41
▸ MAP4K2 Q12851 1/20 0.41
▸ HIPK4 Q8NE63 1/20 0.41
▸ SRPK1 Q96SB4 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ MAP3K20 Q9NYL2 1/20 0.41
▸ STK17A Q9UEE5 1/20 0.41
▸ MAP4K5 Q9Y4K4 1/20 0.41
▸ GRM5 P41594 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ RIOK2 Q9BVS4 1/20 0.40
▸ NR3C2 P08235 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14302169 0.84 RAB9A (0.46) KDRALDH1A1GAANPC1RAB9A
SCHEMBL1464421 0.78 AR (0.59) ARGRM5RORCALDH1A1GAA
SCHEMBL14300149 0.78 CLK4 (0.50) KDRCLK2MAP4K2HIPK4SRPK1
SCHEMBL16253003 0.76 AR (0.58) ARKDRCLK2IRAK1NEK4
SCHEMBL14300160 0.75 AR (0.55) ARKDRCLK2IRAK1NEK4
SCHEMBL3967416 0.72 AR (0.52) ARGRM5RORCSORT1
SCHEMBL26624236 0.72 AR (0.57) ARKDRCLK2IRAK1NEK4
SCHEMBL1464739 0.72 CNR1 (0.46) CLK4STK17AALDH1A1GAANPC1
SCHEMBL16637563 0.71 KDR (0.55) ARKDRCLK2IRAK1NEK4
SCHEMBL3192275 0.71 L3MBTL1 (0.55) ARKDRCLK2IRAK1NEK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 AR 540/4885KDR 1381/4885CLK2 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback